T.M. Kim

Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab)

Mathias Rummel, T.M. Kim, Franco Aversa et al. · Annals of Oncology · 2016 · 142 citations · Full text

Lymphoid Neoplasia, Intravenous Administration, Medicine +6

LBA52 Tepotinib + osimertinib for EGFRm NSCLC with MET amplification (METamp) after progression on first-line (1L) osimertinib: Initial results from the INSIGHT 2 study

Julien Mazières, T.M. Kim, Boon Khaw Lim et al. · Annals of Oncology · 2022 · 40 citations

Oncology, Met Amplification, Egfrm Nsclc +5

Ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with CT and crizotinib (CRZ): Results from the confirmatory phase 3 ASCEND-5 study

Giorgio V. Scagliotti, T.M. Kim, Lucio Crinò et al. · Annals of Oncology · 2016 · 33 citations

Ascend-5 Study, Ceritinib Vs Chemotherapy, Medicine +9

Dabrafenib in Patients with Braf V600E-Mutant Advanced Non-Small Cell Lung Cancer (Nsclc): a Multicenter, Open-Label, Phase Ii Trial (Brf113928)

David Planchard, T.M. Kim, Julien Mazières et al. · Annals of Oncology · 2014 · 28 citations

Oncology, Phase Ii Trial, Medicine +7

Copy Number Variations in Normal Karyotype Acute Myeloid Leukaemia and their Association with Treatment Response

Kyung Im Kim, T.M. Kim, In‐Wha Kim et al. · Basic & Clinical Pharmacology & Toxicology · 2012 · 13 citations